Table 3.

Relationship of plasma vWF activity with clinical factors in patients with heart failure and atrial fibrillation after anticoagulation therapy

Clinical factors	Number of cases	vWF activity (%)
		< 267.5%	≥ 267.5%	χ2/t	P
Sex
Male	74	44	30	0.039	0.843
Female	52	30	22
Age
< 70 years	54	30	24	0.096	0.757
≥ 70 years	72	38	34
Coronary heart disease
Yes	70	32	38	2.806	0.094
No	56	34	22
Hypertension
Yes	68	46	22	0.002	0.961
No	58	39	19
Diabetes
Yes	44	18	26	5.237	0.002
No	82	51	31
Myocardial ischemia
Yes	46	16	30	11.674	0.001
No	80	53	27
Old myocardial infarction
Yes	41	14	27	12.181	0.000
No	85	57	28
Atherosclerosis of the lower extremities
Yes	58	12	46	43.273	0.000
No	68	54	14
Cardiac function classification
III	56	26	30	0.514	0.473
IV	70	37	33
BNP (pg/L)	86/40	1162.83 ± 759.38	1480.47 ± 1092.20	-0.944	0.358
D-DI (µg/L)	79/47	1.49 ± 1.16	2.27 ± 1.65	-1.421	0.167

Note: Von Willebrand factor (vWF); B-type natriuretic peptide (BNP); D-dimer (D-DI)